DexCom, Inc. — FY2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This annual filing does not provide a clear standalone Q4 financial-results summary; figures below compare full-year 2020 with full-year 2019.
Business context
Dexcom develops and sells continuous glucose monitoring (CGM) systems. Its principal product was the G6, with disposable sensors and reusable hardware. The company was pursuing regulatory approvals for its next-generation G7 system and partnered with insulin-delivery and data companies to integrate CGM technology.
Financial performance and liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $1,926.7 million | $1,476.0 million | +31% |
| Gross profit / gross margin | $1,280.1 million / 66% | $931.5 million / 63% | Margin +3 percentage points |
| Operating income | $299.5 million | $142.3 million | +$157.2 million |
| Net income | $493.6 million | $101.1 million | +$392.5 million |
| Diluted earnings per share | $5.06 | $1.10 | +$3.96 |
| Cash from operations | $475.6 million | $314.5 million | +$161.1 million |
- Revenue growth was primarily driven by higher disposable-sensor sales and a larger worldwide customer base. Sensors and other revenue accounted for 81% of sales, versus 78% in 2019. Pricing pressure partly offset growth.
- Gross-margin improvement reflected revenue growth and manufacturing/design efficiencies. Operating expenses rose 24% to $980.6 million: R&D increased 32% to $359.9 million and SG&A rose 20% to $620.7 million.
- FY2020 net income included a substantial tax benefit: Dexcom released $287.2 million of deferred-tax valuation allowance, recording $285.5 million of that release as an income-tax benefit. The reported $493.6 million net income therefore materially exceeded $225.0 million of pretax income.
- Cash, cash equivalents and short-term marketable securities totaled $2.71 billion at year-end, up from $1.53 billion. Current assets were $3.42 billion and current liabilities $614.1 million.
- Investing cash outflow was $1.018 billion, primarily reflecting $807.7 million of net marketable-security purchases and $199.0 million of capital expenditures. Financing cash inflow was $912.1 million, principally net proceeds from the 2025 convertible notes, partly offset by repurchases of 2022 notes.
- Convertible-note principal outstanding was $2.0575 billion: $850.0 million due 2023 and $1.2075 billion due 2025. The balance-sheet carrying amount was $1.6672 billion. The $200 million revolving facility had no borrowings; $193.7 million remained available after letters of credit.
Material changes versus FY2019
- Revenue increased 31%; operating income more than doubled, while reported net income rose sharply in part because of the deferred-tax valuation-allowance release.
- Distributor-channel revenue grew to 75% of total from 69%; direct-channel share declined to 25% from 31%. Four significant distributors each represented at least 10% of revenue.
- International revenue rose to $417.2 million, or 22% of total, from $314.5 million, or 21%.
- Inventory increased to $234.7 million from $119.8 million. Excess and obsolete inventory charges increased to $24.4 million from $14.1 million.
- Dexcom issued $1.2075 billion of 0.25% convertible notes due 2025 and repurchased or converted its remaining 2022 notes. Interest expense rose to $84.7 million from $60.3 million.
Outlook, commentary and risks
- The filing gives no quantified revenue or earnings guidance. Management stated that cash, marketable securities, expected operating cash flows and available credit should cover anticipated needs for at least 12 months and generally fund the ongoing core business.
- Dexcom reported COVID-19-related operating costs, sales and clinical-trial disruption, and supply-chain interruptions affecting G7 development. The company said the pandemic’s eventual effect on financial results and guidance was uncertain.
- G7 was under regulatory review, with a smaller, combined disposable wearable and shorter expected warm-up among its planned features. Timing, regulatory approval, manufacturing scale-up and customer transition remain execution risks.
- Key risks include reimbursement and pricing pressure, competition, manufacturing capacity and single-source suppliers, reliance on distributors, product quality and liability, privacy/cybersecurity, and complex medical-device regulation.
- Dexcom disclosed up to $275 million of potential future Verily milestone payments, payable in cash or shares at Dexcom’s election. It reported no currently pending legal proceeding expected to have a material adverse effect, while noting ordinary-course claims and litigation.
- The auditor issued an unqualified opinion on the financial statements and reported effective internal control over financial reporting as of December 31, 2020.
Important facts for investors to verify
- Separate the $285.5 million tax benefit from recurring operating performance when assessing FY2020 earnings.
- Review convertible-note repayment, conversion, potential dilution and cash-settlement terms, including maturities in 2023 and 2025.
- Assess dependence on distributors: four significant distributors each generated at least 10% of 2020 revenue, and distributor sales represented 75% of revenue.
- Monitor G7 regulatory timing, production readiness, COVID-related supply constraints and the effects of elevated inventory and obsolescence charges.
- Check the assumptions behind reimbursement, rebate and claim-denial estimates, which management and the auditor identified as significant revenue-estimation judgments.